Panagiotis Ferentinos

A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study

Jesse J. Swen, Cathelijne H. van der Wouden, Lisanne E. N. Manson et al. · The Lancet · 2023 · 462 citations · Full text

Drug Safety, Adverse Drug Reactions, Pharmacoepidemiology +9

Major Depression and the Degree of Suicidality: Results of the European Group for the Study of Resistant Depression (GSRD)

Markus Dold, Lucie Bartova, Gernot Fugger et al. · The International Journal of Neuropsychopharmacology · 2018 · 83 citations · Full text

Hippocampal pathology in amyotrophic lateral sclerosis: selective vulnerability of subfields and their associated projections

Foteini Christidi, Efstratios Karavasilis, Michail Rentzos et al. · Neurobiology of Aging · 2019 · 80 citations · Full text

Neurodegenerative Diseases, Amyotrophic Lateral Sclerosis, Neuroanatomy +10

Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder

Giuseppe Fanelli, Francesco Benedetti, Siegfried Kasper et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry · 2020 · 73 citations

Risk Prediction, Psychiatry, Psychotic Disorder +10

Psychometric evaluation of the Fatigue Severity Scale in patients with major depression

Panagiotis Ferentinos, V.P. Kontaxakis, B.J. Havaki-Kontaxaki et al. · Quality of Life Research · 2010 · 66 citations

Fatigue Severity Scale, Fatigue Management, Psychopathology +10